Patent EP0562853A1 successfully refreshed from Google Patents.
EP0562853A1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
29-Demethoxyrapamycin for inducing immunosuppression
Assignee: Wyeth LLC
•
Filing: 1993-03-25
•
Granted: —
•
Expires: 2013-03-25
Abstract
Abstract This invention relates a method of inducing immunosuppression in a mammal in need thereof which comprises, administering an anti-rejection effective amount of 29-demethoxyrapamycin alone or in combination with one or more anti-rejection chemotherapeutic agents.
Inventors
- 👤 Suren Nath Sehgal
- 👤 Jay Joseph Armstrong
- 👤 Chee Ping Eng
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-08 03:49
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61K38/00; A61K38/04; A61K38/12; A61K38/13; A61P; A61P37/00; A61P37/02; A61P37/06
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
15 words
Use of 29-demethoxyrapamycin in the preparation of a medicament for inducing immunosuppression in a mammal.
Claim 2
Dependent Claim
21 words
Use of 29-demethoxyrapamycin in the preparation of a medicament for preventing or treating organ or tissue transplantation rejection in a mammal.
Claim 3
Dependent Claim
35 words
A use according to Claim 2 wherein the transplanted organ or tissue is selected from the group consisting of kidney, heart, liver, lung, bone marrow, pancreas (islet cells), cornea, small bowel, skin and heart valve.
Claim 4
Dependent Claim
27 words
A use according to any one of Claims 1 to 3 in which the medicament comprises a combination of 29-demethoxyrapamycin and one or more anti-rejection chemotherapeutic agents.
Claim 5
Dependent Claim
28 words
A use according to Claim 4 wherein the anti-rejection chemotherapeutic agent is selected from one or more of azathioprine, corticosteroids, cyclophosphamide, rapamycin, cyclosporin A, FK-506, OKT-3 and ATG.
Claim 6
Dependent Claim
26 words
A use according to any one of Claims 1 to 5 in which the medicament is adapted for administration orally, parenterally, intranasally, intrabronchially, transdermally or rectally.
Claim 7
Dependent Claim
21 words
A pharmaceutical composition which comprises a combination of 29-demethoxyrapamycin and one or more anti-rejection chemotherapeutic agents and a pharmaceutically acceptable carrier.
Claim 8
Dependent Claim
25 words
A product containing 29-demethoxyrapamycin and a anti-rejection chemotherapeutic agent as a combined preparation for simultaneous, separate or seqential use in inducing immunosuppression in a mammal.
Claim 9
Dependent Claim
35 words
A composition or product according to Claim 7 or Claim 8 wherein the anti-rejection chemotherapeutic agent is selected from azathioprine, corticosteroids, cyclosporin A, FK-506, OKT-3 and ATG, or a combination of any of the foregoing.
References Cited (Backward Citations)
US3929992A
Cited
US4375464A
Cited
EP0184162A2
Cited
US4894366A
Cited
EP0401747A2
Cited
WO1992014737A1
Cited
US5078999A
Cited
US5080899A
Cited
US5091389A
Cited
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.